Skip to contentSkip to navigation

Your Questions — 8 minutes

HPV: The leading cause of cervical cancer

Among sexually transmitted and blood-borne infections (STBBIs), those caused by the human papillomavirus (HPV) are the most common. While most of these infections are benign and of no consequence, some cause more damage, including cervical cancer.

A contagious and sometimes cancer-causing virus

An estimated 75% of sexually active Canadians of both sexes will be infected with HPV during their lifetimes.[1] This is not surprising, as the virus is extremely contagious. Skin-to-skin contact in the genital area, even without penetration, is often enough to spread it.

In addition, there are more than 200 types of HPV, around 40 of which can infect the genital tract. During their lifetime, an individual can therefore be infected by more than one type of HPV, or even several times by the same type. Fortunately, the vast majority of these infections disappear on their own, very often without the infected individuals knowing.

However, some types of HPV can lead to the appearance of genital warts (condylomas), while around 15 others can cause cancer. These so-called high-risk types of HPV can cause cancer of the penis in men, of the throat, mouth or anus in both sexes and, in women, of the vulva, vagina and, more frequently, the cervix.[2]

In 2019, an estimated 1,350 Canadian women were diagnosed with cervical cancer and 410 died from the disease.[3] Why does HPV, which disappears on its own in the majority of infected individuals, turn into an agent of cancer in some women?

Predisposing conditions

When a high-risk type of HPV infects a cell in the cervix, it alters the way the cell functions, causing it to reproduce new HPV particles. If the virus is present for long enough, proteins involved in this reprogramming will trigger uncontrolled multiplication of infected cells. Normally, our immune system should be able to recognize these abnormal cells and neutralize them before they invade the organs. But certain situations, or combinations of situations, allow them to escape our defence mechanisms.[4]

Risk factors for cervical cancer

  • Presence of high-risk HPV (HPV 16, 18 or 31)
  • Weakening of the immune system (medication, AIDS)
  • Smoking (associated with greater persistence of the virus)
  • Early sexual relations and multiple sexual partners (increased exposure to multiple types of HPV)
  • Concomitant STBBI (double the risk if co-infected with chlamydia)

The time factor

As the number of abnormal cells increases, a lesion forms on the cervix. This lesion, still benign, is made up of what are known as precancerous cells. Eventually it will be detectable during an examination of the cervix, and analysis of the cells under the microscope (gynaecological cytology or Pap test) will determine its nature. If this lesion is not detected or treated, it will take many years – 10 to 20 or more – before it becomes cancerous and invades the surrounding tissues.

The problem is that there are generally few symptoms in the early stages of cervical cancer, and the cancer’s progress often goes unnoticed. The most typical symptom is unusual vaginal bleeding after intercourse, between periods or after menopause. There may be other causes for this bleeding, and it is not automatically linked to cancer. At the very least, you should talk to your doctor about this bleeding. Other symptoms of a cancerous lesion range from pain and discomfort during intercourse to a foul-smelling vaginal discharge.[5]

Tools to combat HPV and cervical cancer

As with all cancers, the fight against cervical cancer involves effective preventive measures combined with techniques for early detection. In addition, treatments are available that can improve the survival rate of those affected.

Vaccination against HPV

In 2008, the Quebec government introduced a vaccination program against human papillomavirus infections. Initially limited to girls in the fourth year of elementary school, the program has been gradually extended to boys and other high-risk groups of both sexes.[6] This program is probably the most important tool in the fight against cervical cancer.

Although it is still too early to measure its effect on the incidence rate of cervical cancer, preliminary results for cases of condylomas and high-risk HPV are very encouraging.

A study published in late 2018 in the Journal of Obstetrics and Gynaecology Canada found a 45% reduction in anogenital warts in girls aged 15 to 19, and a 21% reduction in boys of the same age in Canada since vaccination was introduced. In addition, the risk of developing cervical lesions fell by 86% in some cases.[7]

In Sweden, a vaccination program is also believed to have resulted in a substantial drop in the risk of developing cervical cancer. According to a study published in 2020, the cumulative incidence of cervical cancer was 94 cases per 100,000 among unvaccinated women, and 47 cases per 100,000 among vaccinated women. The results were even more spectacular in women who were vaccinated before age 17, with only four cases per 100,000.[8]

A new primary screening method Since cervical cancer does not appear until many years after lesions develop, detecting lesions during the gynaecological exam, and being able to identify high-risk types of HPV, are the foundations of the Cervical Cancer Screening Program.

Over the past 50 years, the Pap test, which detects lesions on the cervix, has greatly improved the survival rate for cervical cancer. However, this primary screening method will soon be replaced by direct detection of high-risk types of HPV, a much more accurate test. Studies indicate that the ability of HPV tests to detect precancerous lesions is 94.6%, versus 55.4% for the Pap test.[9]

Further studies are underway to confirm the possibility of vaginal self-sampling for this test, a solution the vast majority of women would prefer, and which could help boost participation in the screening program.

Learn more about this Biron's screening tests (HPV test and cytology)

Effective treatments Most women who have cervical cancer undergo surgery, most often a radical hysterectomy, which involves removal of the cervix, uterus, surrounding tissues and upper vagina. Depending on the case, this operation may be combined with radiotherapy and chemotherapy. Thanks to these treatments, the five-year survival rate for everyone diagnosed is 74%,[10] rising to more than 92% for cases detected early (44% of cases).[11]

As with other cancers, there are regular proposals to improve cervical cancer treatment. A recent study, led by the Canadian Cancer Trials Group in collaboration with the Gynecologic Cancer InterGroup, showed that radical hysterectomy could in many cases be beneficially replaced by simple hysterectomy (uterus and cervix), which involves far fewer side-effects and has less impact on quality of life and sexual health.[11]

However, these treatments could one day become obsolete. Thanks to vaccination against HPV, along with screening and improved follow-up of abnormal results, it may be possible to eradicate cervical cancer in Canada by 2040.[12]

Get tested now

Take charge of your health with periodic cervical cancer screening

Book a screening, or contact Biron Groupe Santé customer service at 1 833 251-6006.

Sources12
  1. The Society of Obstetricians and Gynecologists of Canada. “What is HPV?” HPVinfo.ca, https://www.hpvinfo.ca/what-is-hpv/ [accessed on September 19, 2023].
  2. Ministère de la Santé et des Services sociaux. “Human papillomavirus (HPV),” https://www.quebec.ca/en/health/health-issues/stbbis/human-papillomavirus-hpv [accessed on September 19, 2023].
  3. Public Health Agency of Canada. “Cervical Cancer,” https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/cervical-cancer.html [accessed on September 19, 2023].
  4. National Cancer Institute. “HPV and Cancer,” https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer#top [accessed on September 19, 2023].
  5. NHS Inform. “Cervical Cancer,” https://www.nhsinform.scot/illnesses-and-conditions/cancer/cancer-types-in-adults/cervical-cancer [accessed on September 19, 2023].
  6. Ministère de la Santé et des Services sociaux. “Human Papillomavirus (HPV) Vaccination Program, History of the program,” https://www.quebec.ca/en/health/advice-and-prevention/vaccination/human-papillomavirus-hpv-vaccination-program/history-of-the-program [accessed on September 19, 2023].
  7. M. Steben, M.T. Thompson, C. Rodier et al. “A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada,” Journal of Obstetrics and Gynaecology Canada, Vol. 40, #12, December 18, 2018,https://www.jogc.com/article/S1701-2163(18)30462-6/fulltext [accessed on September 26, 2023].
  8. J. Lei, A. Ploner, K.M. Elfström, J. Wang et al. “HPV Vaccination and the Risk of Invasive Cervical Cancer,” New England Journal of Medicine, Vol. 383, pp. 1340-1348, October 1, 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa1917338 [accessed on September 26, 2023].
  9. Biron. “Cervical cancer: Pap test replaced by an HPV test,” News, June 9, 2022, https://www.biron.com/fr/actualites/sante-a-a-z/nouveau-mode-depistage-cancer-col-uterus/ [accessed on September 19, 2023].
  10. Canadian Cancer Society. “Survival statistics for cervical cancer,” https://cancer.ca/en/cancer-information/cancer-types/cervical/prognosis-and-survival/survival-statistics [accessed on October 5, 2023].
  11. CHU de Québec. “Avancée majeure dans le traitement du cancer du col de l’utérus,” News, June 5, 2023, https://www.chudequebec.ca/actualites/avancee-majeure-dans-le-traitement-du-cancer-du-co.aspx [accessed on September 19, 2023].
  12. Canadian Partnership Against Cancer. Action Plan for the Elimination of Cervical Cancer in Canada, 2020-2030, https://s22457.pcdn.co/wp-content/uploads/2020/11/Elimination-cervical-cancer-action-plan-EN.pdf [accessed on October 5, 2023].